CD8+ T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein

Transplantation

Volumn 82, Issue 11, 2006, Pages 1510-1517

  Ferrari Lacraz, Sylvie ^a,b   Zheng, Xin Xiao ^a   Fueyo, Alberto Sanchez ^a   Maslinski, Wlodzimierz ^a,c   Moll, Thomas ^d   Strom, Terry B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

^d Telos Pharmaceuticals LLC   (United States)

Author keywords

Cytokines; Immunotherapy; Suppression; T lymphocytes; Tolerance

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC GAMMA 2A PROTEIN;

ALLOGRAFT; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOARCHITECTURE; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT REJECTION; INTERLEUKIN-15; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MICE; MICE, MUTANT STRAINS; RECEPTORS, INTERLEUKIN-15;

EID: 33845712659     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000243168.53126.d2     Document Type: Article

References (38)

1. + T cells. J Immunol 1999; 163: 2358.
2. + T cell tolerance and linked suppression. J Immunol 1999; 163: 4805.
3. + T cells can trigger allograft rejection. J Immunol 2000; 165: 1111.
4. + T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164: 512.
5. + T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104: 1715.
6. + T cells in vivo by IL-15. Immunity 1998; 8: 591.
7. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771.
8. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9: 669.
9. + T cells. J Exp Med 2001; 193: 219.
10. Steiger JPWN, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allograft. J Immunol 1995; 155: 489.
11. Li XC, Roy-Chaudhury P, Hancock WW, et al. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol 1998; 161: 890.
12. Kim Y, Maslinski W, Zheng XX, et al. Targeting the IL-15 receptor with an antagonist IL-15/Fc protein blocks delayed type hypersensitivity. J Immunol 1998; 160: 5742.
13. Zheng XX, Sanchez-Fueyo A, Sho M, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19: 503.
14. Ferrari-Lacraz S, Zheng XX, Kim YS, et al. An antagonist IL-15/Fc protein prevents costimulation blockade- resistant rejection. J Immunol 2001; 167: 3478.
15. O'Connell PJ, Pacheco-Silva A, Nickerson PW, et al. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993; 150: 1093.
16. Faustman DL, Steinman RM, Gebel HM, Hauptifeld V. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci USA 1984; 81: 3864.
17. Faustman D, Hauptfeld V, Lacy P, Davie J. Prolongation of murine islet allograft survival by treatment of islets with antibody directed to Ia determinants. Proc Natl Acad Sci USA 1981; 78: 5156.
18. Steurer W, Nickerson PW, Steele AW, et al. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995; 155: 1165.
19. + T cell-mediated intestinal allograft rejection. J Immunol 2001; 167: 4796.
20. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry (CFSE). J Immunol Methods 1994; 171: 131.
21. + T cell precursor frequency (CFSE). Transplantation 1999; 67: 1281.
22. Jones ND, Van Maurik A, Hara M, et al. T cell activation, proliferation, and memory after cardiac transplantation in vivo. Ann Surg 1999; 229: 570.
23. + T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med 2002; 8: 233.
24. Habiro K, Shimmura H, Kobayashi S, et al. Effect of inflammation on costimulation blockade-resistant allograft rejection. Am J Transplant 2005; 5: 702.
25. Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 2005; 174: 6648.
26. + T cell anergy in vivo. J Immunol 2001; 167: 4936.
27. Zheng XX, Gao W, Donskoy E, et al. An Antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation 2006; 81: 109.
28. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
29. Smith XG, Bolton EM, Ruchatz H, et al. Selective blockade of IL-15 by soluble IL-15 receptor α-chain enhances cardiac allograft survival. J Immunol 2000; 165: 3444.
30. Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105: 865.
31. + T cells. Eur J Immunol 1998; 28: 3137.
32. Li XC, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nature Med 2001; 7: 114.
33. + T cell clones allow B cell growth and differentiation. Eur J Immunol 1995; 25: 2972.
34. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nature Med 2005; 11: 1059.
35. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002; 100: 3633.
36. Kawamura T, Koka R, Ma A, Kumar V. Differential roles for IL-15R α-chain in NK cell development and Ly-49 induction. J Immunol 2003; 171: 5085.
37. Larsen CP, Elwood ET, Alexender DZ, et al. Long-term acceptance of skin and cardiac allograft after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
38. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.